Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2034517 | Biologicals | 2009 | 8 Pages |
Abstract
The present work evaluates both in vitro and in vivo antitumor activity of BPB-modified BthTX-I and its cationic synthetic peptide derived from the 115–129 C-terminal region. BPB-BthTX-I presented cytotoxicity of 10–40% on different tumor cell lines, which were also susceptible to the lytic action of the synthetic peptide. Injection of the modified protein or the peptide in mice, 5 days after transplantation of S180 tumor cells, reduced 30 and 36% of the tumor size on day 14th and 76 and 79% on day 60th, respectively, when compared to the untreated control group. Thus, these antitumor properties might be of interest in the development of therapeutic strategies against cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
Luiz Carlos Gebrim, Silvana Marcussi, Danilo L. Menaldo, Carla S.R. de Menezes, Auro Nomizo, Amélia Hamaguchi, Elisângela P. Silveira-Lacerda, Maria Inês Homsi-Brandeburgo, Suely V. Sampaio, Andreimar M. Soares, Veridiana M. Rodrigues,